Navigation Links
CCHRINT Announces FDA Reported Psychiatric Drug Side Effects Search Engine
Date:8/4/2009

as "anecdotal" by the FDA even when serious side effects number in the thousands. The FDA approves the majority of psychiatric drugs only after Phase 2 (short term) clinical trials. However, once the drugs are out in the consumer market, the FDA is supposed to require longer clinical trials, or post-marketing studies of the drugs, however this rarely happens. Subsequently, dangerous and deadly drugs have been left without black box warnings, or on the market for far too long. The best "signal" event for the FDA to direct its resources in identifying or pulling dangerous drugs is what is happening out in the real world, with consumers and patients, not in a controlled short term clinical trial, funded by the pharmaceutical companies seeking approval for their drugs to go to market.

For years the information contained in the FDA's MedWatch reporting system has been inaccessible and therefore virtually useless for consumers and doctors. CCHR's stance has always been that consumers have the right to this information for then 6 and only then 6 can consumers have full "informed consent" regarding the risks of psychiatric drugs, and so it has provided this database as a free public service.

The psychiatric drug search engine features a promotional video as well as an instructional video for users on CCHR's newly launched website so they can get the information from the database they are looking for in the shortest amount of time.

About The Citizens Commission on Human Rights:


Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. Samarion Announces Partnership With Adesta to Install the SamarionSolution Nationwide
2. EPIX Pharmaceuticals, Inc. Announces August 25, 2009 for the Auction Sale of Equipment and September 30, 2009 for the Auction Sale of the Intellectual Property
3. Ferring Pharmaceuticals Announces Trade Name FIRMAGON(R) (degarelix for injection) for Advanced Prostate Cancer Treatment
4. Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 First Quarter Financial Results
5. Presidents Council Announces Top 5 Winners of 2009 National Presidents Challenge
6. Arcadia Resources Announces Webcast of Its Fiscal 2010 First Quarter Conference Call
7. West Announces Second Quarter 2009 Results
8. Rigel Announces Second Quarter 2009 Financial Results
9. CorVel Announces Revenues and Earnings
10. Cardiome Announces Management Transition
11. Hologic Announces Third Quarter Fiscal 2009 Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
CCHRINT Announces FDA Reported Psychiatric Drug Side Effects Search Engine
CCHRINT Announces FDA Reported Psychiatric Drug Side Effects Search Engine
Breaking Medicine News(10 mins):Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 2Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 3Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 4Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 5Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 6Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 7Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 8Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 9Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 10Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 11Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 12Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 13Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 14Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 15Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 16Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 17Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 18Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 19Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 20Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 21Health News:People living in poorer neighborhoods at increased risk for death, worse health risks 2Health News:AUL Action Challenges Planned Parenthood to Reveal Financial Interest in Health Care Legislation 2Health News:Health Education Solutions Expands Online Course Offerings with eLearning Curricula Developed by American Heart Association 2
Other Medicine News:Health News:Samplify Evolves Business Model From IP Developer to Semiconductor Supplier; Now Targets Multi-Billion Dollar Market 2Health News:Leading the Way in Cosmetic Surgery Los Angeles Surgeon and Beauty Expert, Dr. Christine Petti Offers Minimally Invasive SmartLipo™ – The Smart Way to Lose Fat 2Health News:Leading the Way in Cosmetic Surgery Los Angeles Surgeon and Beauty Expert, Dr. Christine Petti Offers Minimally Invasive SmartLipo™ – The Smart Way to Lose Fat 3Health News:Designs for Health Acquires eHealthPro™ and eNatro™ Practice Management Software 2Health News:Designs for Health Acquires eHealthPro™ and eNatro™ Practice Management Software 3Health News:Designs for Health Acquires eHealthPro™ and eNatro™ Practice Management Software 4Health News:Decision Intelligence Delivers Marketing Contact Optimization Solutions 2Health News:Decision Intelligence Delivers Marketing Contact Optimization Solutions 3Health News:FDA Adds Three Months to Review of Takeda's New Drug Application for TAK-390MR 2
Breaking Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Elsevier Selects BrainTrack Directory as Supplier of College Data 2Elsevier Selects BrainTrack Directory as Supplier of College Data 3Elsevier Selects BrainTrack Directory as Supplier of College Data 4AstraZeneca Medicare Part D Patient Assistance Program No Longer Requires Co-Pays 2First Time Father to Be Quits Smoking Wins 245 000 in The QuitCash Challenge 28TM 29 61753 1First Time Father to Be Quits Smoking Wins 245 000 in The QuitCash Challenge 28TM 29 61753 2First Time Father to Be Quits Smoking Wins 245 000 in The QuitCash Challenge 28TM 29 61753 3Teamsters Oppose Senate Plan to Tax Health Insurance Companies 61750 1Monogram Energy Inc Acquires Triad Therapeutics Inc 61747 1Monogram Energy Inc Acquires Triad Therapeutics Inc 61747 2